PL1940817T3 - Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych - Google Patents

Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych

Info

Publication number
PL1940817T3
PL1940817T3 PL06792225T PL06792225T PL1940817T3 PL 1940817 T3 PL1940817 T3 PL 1940817T3 PL 06792225 T PL06792225 T PL 06792225T PL 06792225 T PL06792225 T PL 06792225T PL 1940817 T3 PL1940817 T3 PL 1940817T3
Authority
PL
Poland
Prior art keywords
treatment
brain barrier
cognitive impairment
improved blood
barrier permeability
Prior art date
Application number
PL06792225T
Other languages
English (en)
Inventor
Alfred Maelicke
Original Assignee
Galantos Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1940817(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galantos Pharma Gmbh filed Critical Galantos Pharma Gmbh
Publication of PL1940817T3 publication Critical patent/PL1940817T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06792225T 2005-09-22 2006-09-22 Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych PL1940817T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05020721A EP1777222A1 (en) 2005-09-22 2005-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US78024306P 2006-03-07 2006-03-07
EP06792225A EP1940817B1 (en) 2005-09-22 2006-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
PCT/EP2006/009220 WO2007039138A1 (en) 2005-09-22 2006-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Publications (1)

Publication Number Publication Date
PL1940817T3 true PL1940817T3 (pl) 2011-03-31

Family

ID=35717553

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06792225T PL1940817T3 (pl) 2005-09-22 2006-09-22 Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych

Country Status (10)

Country Link
US (1) US20080261954A1 (pl)
EP (2) EP1777222A1 (pl)
CN (1) CN101287719A (pl)
CA (1) CA2623114A1 (pl)
DK (1) DK1940817T3 (pl)
ES (1) ES2348334T3 (pl)
PL (1) PL1940817T3 (pl)
PT (1) PT1940817E (pl)
SI (1) SI1940817T1 (pl)
WO (1) WO2007039138A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
CN102007129B (zh) * 2008-04-14 2014-05-07 神经动力生命科学公司 用作治疗人类脑疾病的前药的雪花胺衍生物
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2456434A1 (en) * 2009-07-23 2012-05-30 Shire LLC Galantamine amino acid and peptide prodrugs and uses thereof
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
PT3417862T (pt) 2012-07-27 2021-08-06 Neurodyn Life Sciences Inc Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103193787B (zh) * 2013-03-11 2015-10-28 华中科技大学 具有神经保护作用的石蒜伦碱类化合物及其制备方法
CN103204860B (zh) * 2013-03-11 2015-10-28 华中科技大学 具有神经保护作用的石蒜科生物碱类化合物
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN114621242A (zh) * 2020-12-11 2022-06-14 哈药(北京)生物科技有限公司 加兰他敏的衍生物及制剂
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
CN116217641A (zh) * 2023-03-01 2023-06-06 上海原思标物科技有限公司 吗啡-D3-6-β-D-葡萄糖醛酸苷的合成方法及其中间体化合物
US12208167B1 (en) 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine
US12551491B1 (en) 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
US4981849A (en) * 1989-02-23 1991-01-01 Smithkline Beecham Corporation Alpha-adrenergic receptor antagonists
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU8742198A (en) * 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
ATE306264T1 (de) * 1998-12-11 2005-10-15 Bonnie M Davis Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040266659A1 (en) * 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming

Also Published As

Publication number Publication date
CN101287719A (zh) 2008-10-15
WO2007039138A1 (en) 2007-04-12
PT1940817E (pt) 2010-10-11
DK1940817T3 (da) 2010-10-18
CA2623114A1 (en) 2007-04-12
EP1940817A1 (en) 2008-07-09
SI1940817T1 (sl) 2010-10-29
ES2348334T3 (es) 2010-12-02
US20080261954A1 (en) 2008-10-23
EP1777222A1 (en) 2007-04-25
EP1940817B1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
SI1940817T1 (sl) Holinergični ojačevalci z izboljšano hematoencefalno barierno propustnostjo za zdravljenje bolezni, ki spremljajo upad kognitivnih sposobnosti
PL1972098T3 (pl) Zapytania roamingu przed powiązaniem/uwierzytelnieniem
GB0518390D0 (en) Therapeutic compounds
IL195330A0 (en) Permeability of blood-brain barrier
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
SI2001892T1 (sl) Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni
IL186299A0 (en) Pharmacokinetically improved compounds
GB0518237D0 (en) Therapeutic compounds
HU0500170D0 (en) New compounds with therapeutic effects
GB0509326D0 (en) Therapeutic compounds
IL208070A0 (en) Myxoma virus mutants for therapeutic treatment
IL183379A0 (en) Processes for the preparation of linezolid intermediate
GB0509573D0 (en) Therapeutic compounds
GB0518361D0 (en) Therapeutic compounds
GB0522881D0 (en) Therapeutic compounds
FR2894432B1 (fr) Ameliorant de panification
GB0522130D0 (en) Therapeutic compounds
GB0526107D0 (en) Therapeutic Compounds
DE502006006979D1 (de) Rinnenkörper
IL190182A0 (en) 2-aminoalcohols for the treatment of neurodegenerative diseases
GB0518235D0 (en) Therapeutic compounds
IL185344A0 (en) Pharmacokinetically improved compounds
GB2422135B (en) Privacy shields
ES1060422Y (es) Almohada terapeutica de cascara de alforfon.
GB0515580D0 (en) Therapeutic compounds